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BY4741 haploid wild type yeast was mutagenized with EMS

,,.

,.

Plated onto YPD media containing:
Nystatin - selects for ergosterol biosynthesis mutants
Squalestatin - inhibits squalene synthase, mimic of erg9 mutation
Cholesterol - restores growth, supplants ergosterol
Picked 200 colonies

"I ,.

Replica plated all 200 colonies onto YPD+squalestatin and
YPD+squalestatin+ergostero 1plates
Screened for colonies that only grew in the presence of ergosterol
134 colonies grew on both plates, only 66 demonstrated ergosterol dependent
growth

,,.

,.

Grew the 66 positive colonies in liquid YPD+squalestatin+ergosteroi media and
screened for fameso 1accumulation
20 colonies did not accumulate FOH
46 colonies accumulated 1-60 mg FOH/L
9 colonies accumulated more than 50 mg FOH/L

,,.

,.

Introduce ERG9 Knockout mutations in the 8 of the 9 selected lines,
First, verify for no growth without ergosterol addition to the media,
follow-up with PCR confirmation of erg9 KO, then screened for FOH
accumulation by 8 independent colonies from each line.
Eleven of 64 independent lines accumulated more than 70 mg/L FOH in small
scale test tube culture.

Figure 15
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1

2

METHOD AND SYSTEM FOR TERPENE
PRODUCTION PLATFORMS IN YEAST

Monoterpenes are well known as the volatile essence of
flowers and plants and such mixtures can account for up to
5% of plant dry weight (Buchanan et al., 2002). Menthol and
camphor are common monoterpenes found in diverse plant
families and whose structural complexity in terms of stereoand regio-chemistry are emphasized in FIG. 2. Besides
providing pleasing fragrances, monoterpenes have been
shown to function as signal molecules in defense mechanisms against pathogens (Hick et al., 1999). Hence,
monoterpenes have the commercial value as flavors, fragrances, essential oils, and as anticancer and antimicrobial
drugs (Burke et al., 1997). Sesquiterpenes (C15) are also
found in essential oils, and many sesquiterpenes possess
antibiotic activities, prompting suggestions that they are
produced by plants as a defense mechanism. Diterpenes
(C20) include gibberellins (plant hormones), vitamin A, as
well as pharmaceutical important metabolites such as taxol,
an exceptional anticancer regent (Barkovich & Liao, 2001).
Triterpenes (C30) include the brassinosteroids, phytosterols
important for lipid membrane composition, and components
of surface waxes, such as oleanolic aid of grapes. Squalene,
the major content of shark liver oil, is a linear triterpene and
common ingredient in cosmetic products (Buchanan et al.,
2002), has special utility as a lubricant for high performance
machinery, and is a common adjuvant in many pharmaceutical formulations (Bhilwade et al., 2010, Huang et al., 2009,
Reddy & Couvreur, 2009). Tetraterpenes (C40) include
carotenoid accessory pigments, like lycopene, the monocyclic gamma-carotene, and the bicyclic alpha- and betacarotenes, which perform essential for the light reactions of
photosynthesis. Longer chain terpenes, so-called polyterpenes, contain more than 8 isoprene units and include
examples like ubiquinone and rubber (Buchanan et al.,
2002).
There are two pathways for terpene biosynthesis in plant
cells. One is the mevalonate pathway pathway (MVA) which
is well established and discovered in the 1960s (Bouvier et
al., 2005). The other is the mevalonate independent pathway,
or more properly referred to as the methylerythritol-phosphate pathway (MEP), which was more recently discovered
(Bouvier et al., 2005). The MEP pathway was first discovered in prokaryote cells, and then confirmed to exist in plant
cells (Barkovich & Liao, 2001). Interestingly, plants utilize
these two pathways to meet different terpene biosynthetic
needs. Sesquiterpenes, sterols, triterpenes and oligoterpenes
(side chain of dolichols) are synthesized in the cytosol via
the MVA pathway, while monoterpenes, diterpenes, teraterpenes, and polyterpenoids are synthesized in chloroplasts
via the MEP pathway using pyruvate and glyceraldehydes3-phosphate as the primary precursors (FIG. 2).
The principal product of the mevalonate pathway is
sterols, for example cholesterol in animal cells, stigmasterol
and campesterol in plant cells, and ergosterol in fungi, which
all play essential roles in establishing the structural integrity
of membranes, establishing permeability and fluidity, and
also serving as signal compounds in cellular communication
(Buchanan et al., 2002). In Saccharomyces cerevisiae, only
the mevalonate pathway is known to operate and no components of the MEP pathway have been found (Maury et al.,
2005). FIG. 3 shows the intermediates and the related genes
involved in the yeast mevalonate pathway (Maury et al.,
2005). Two molecules of acetyl-CoA are condensed by
acetoacetyl-CoA thiolase, which is encoded by ERGl0, to
synthesize acetoacetyl-CoA. A second condensation reaction between acetoacetyl-CoA and acetyl-CoA is then catalyzed by HMG-CoA synthase encoded by ERG13 to yield
3-hydroxy-3methyglutaryl-CoA (HMG-CoA).

CROSS-REFERENCE TO RELATED
APPLICATION

5

This application claims the benefit of provisional patent
application No. 61/730,412, filed Nov. 27, 2012, herein
incorporated by reference.
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FIELD OF THE INVENTION
The presently-disclosed subject matter relates to methods
for producing or generating modified yeast, and the resulting
yeast, and in particular yeast that can be used for various
aspects of terpene production. For example, the subject
matter relates to methods and systems for building terpene
production platforms in yeast which have various introduced
mutations. These platforms or cell lines can be further
modified, e.g. genetically engineered to produce specific
enzymes and/or terpenes.
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20

BACKGROUND OF THE INVENTION
Plants, microorganisms and animals produce a large variety of organic chemical compounds, some of which are used
universally for growth and metabolism and others seem to
play specialized roles in the life cycle of the organism
(Maimone & Baran, 2007). As such, two large classes of
natural products are widely recognized. Primary metabolites
are those essential for live in all eukaryotic organisms, while
specialized metabolites appear to give species specific
advantages for occupying distinct environmental niches.
The distinctive role specialized metabolites play in an organisms natural history, for example how these metabolites
provide protection against microbial challenge, have also
not escape attention for their possible utility in a wide range
of applications. For example, many of the currently used
drugs are derived or inspired from plant-derived specialized
chemicals and are commonly referred to as Natural Products
(Buchanan et al., 2002). Capturing the chemical and structural diversity of Natural Products has recently been identified as a major objective within the scientific community in
large part because of the wide array of applications Natural
Products can have and the resulting economical implications.
Terpenes and terpenoids are a large and diverse family of
Natural Products with more than 55,000 having been identified (Maimone & Baran, 2007). However, based on the
biosynthetic mechanisms responsible for terpenes, chemists
have predicted that only a small fraction of all the possible
terpene compounds have been discovered (Bouvier et al.,
2005). Terpenes are derived from the five carbon isoprene
unit with different combinations of the isoprene units generating different classes of the terpene products. The classification and biosynthesis of terpenoids are based on the
number of five-carbon units they contain as illustrated in
FIG. 1. Monoterpenes (consisting of 10 carbons), sesquiterpenes (15 carbon derivatives), and diterpenes (20 carbon
derivatives), arise from the corresponding intermediates
geranyl diphosphate (GPP), farnesyl diphosphate (FPP), and
geranylgeranyl diphosphate (GGPP). These intermediates in
turn arise by the sequential head to tail condensation of CS
units. Higher order terpenes like triterpene (30 carbons) are
formed from two famesyl units condensed head-to-head.
Likewise, tetraterpenes (40 carbons) are formed from two
geranylgeranyl units condensed head-to-head.
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TABLE 1
Biological activities and commercial applications of typical terpenoids

Class

Biologic activities

Monoterpenoids

Signal molecules and
used as defense
mechanisms against
pathogens

Sesquiterpenoids

Antibiotic, antiturnor,
antiviral, immunosuppressive, and
hormonal activities,
defensive agents or
pheromones
Hormonal activities,
growth regulator,
anti tumor,
antimicrobial and
anti-inflammatory
properties
Membrane
component, steroid
hormones

Diterpenoids

Triterpenoids

Tetraterpenoids

Antioxidants,
photosynthetic
components,
pigments, and
nutritional elements
(vitamins)

Commercial
applications

Examples

Flavors, fragrances,
cleaning products,
anticancer,
antibacterial,
antioxidant, essential
oil, biofuel
Flavors, fragrances,
pharmaceuticals
(antibacterial,
antifungal),
insecticides, biofuels

Limonene, menthol,
camphor, linalool

Nootkatone,
artemisinin, patchoulol,
nerolidol, famesol,
capsidol, famesene,
bisabolene

Anticancer agents,
feedstock for
industrial chemical
applications

Gibherellins, phytol,
taxol, kaurene,
abietadiene, kaurenoic
acid, abietic acid

Biologic markers,
Sterols, hopanoids,
biofuel, skin
squalene,
moisturizers in
botryococcene.
cosmetics,
immunologic adjuvant
in vaccines.
Food additives,
Lycopene, betacolorants, antioxidants carotene

HMG-CoA is reduced by HMG-CoA reductase to yield
mevalonate. This reaction is catalyzed by HMG-CoA reductase, which is encoded by 2 separate loci in yeast. Both loci
appear to compensate for a knockout loss of the other gene.
The CS position of mevalonate is phosphorylated by
mevalonate kinase, encoded by ERG12. Then a second
kinase, phosphomevalonate kinase, encoded by ERGS, catalyzes the successive phosphorylation to yield diphosphomevalonate. In the next step the diphosphomevalonate is
converted into IPP (isopentenyl diphosphate) by mevalonate
diphosphate decarboxylase, encoded by ERG19. IPP
isomerase, encoded by IDil converts IPP into DMAPP
(dimethylallyl diphosphate). The condensation of the CS
building blocks ofIPP and DMAPP into FPP is catalyzed by
FPP synthase, which is encoded by ERG20. FPP can then be
used as substrate for stern! and other isoprenoid biosynthetic
needs.
Recent studies have discovered that FPP is also available
in yeast mitochondria, as evidenced by increasing novel
sesquiterpene production three-times by targeting a sesquiterpene synthase to the mitochondria compartment compared with targeting this same enzyme to the cytosol (Farhi
et al., 2011 ). The origin of FPP in mitochondria could be the
IPP and DMAPP arising in cytosol being imported and
converted in the mitochondria to FPP. Alternatively, a hypothetical leucine metabolism model for the formation of
terpene in S. cerevisiae is also a possibility. The leucine
catabolism pathway (MCC pathway) is known to occur in
the mitochondria of other eukaryotic mammal and plant
cells (Anderson et al., 1998), in mitochondria leucine
metabolite to form 3-Hydroxy-3-methylglutaryl-CoA,
which can be catalyzed by HMGR to produce mevalonic
acid, and then produce IPP and DMAPP through MVA
pathway as shown in FIG. 4 (Carrau et al., 2005). Interest-
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ingly, a yeast line engineered with a chimeric diterpene
synthase targeted to the cytoplasm along with prenyltransferases streamlined for GGPP biosynthesis, yielded 2-3
times more diterpene when the expression vector also provided a leu2 auxotrophic selection marker gene. The interpretation provided by the authors was that the extra leucine
produced by the auxotrophic selection marker gene provided
another source for IPP via the leucine catabolic pathway
(FIG. 4). (Zhou et al., 2012).
Prenyltransferases generate allylic diphosphate esters
GPP, FPP, and GGPP. These compounds can undergo a
variety of reactions, which include cyclization reactions
catalyzed by terpene synthases, yielding diverse terpenes
based on regio- and stereo-chemical constraints built into the
reactions. Prenyltransferases and terpene syntahases utilize
electrophilic reaction mechanisms to mediate the catalytic
reactions (Ohnuma et al., 1996) and typically share a conserved aspartate-rich DDXXD motif thought important for
the initial substrate binding and metal-dependent ionization
step leading to the first reaction carbocation intermediates.
In the prenyltranferase reactions, the allylic diphosphate
ester can be ionized to form a carbocation, then condensed
with a second IPP in another round of elongation.
Terpenes are a very large class of structurally diverse
compounds made by organisms in all kingdoms of life. The
terpenes from plants are perhaps the most extensively
described as evident by well over 100,000 different terpenes
reported in the literature (Buckingham, 2003). Terpenes are
also widely recognized for their diverse utility and applications. For example, taxol, a diterpene widely recognized for
its application as a chemotherapeutic agent, was first isolated from the bark and needles of several Taxits plant
species (Wall and Wani, 1995). Likewise, Artemisinin, a
sesquiterpene isolated from the plant Artemisia annua, has
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been developed as a key pharmacological agent for the
control of malaria (Tu, 2011 ). Patchouli, another sesquiterpene, is a popular aromatic found in colognes, perfumes and
many other household cleaning products (Wu et al., 2006).
Menthol is a monoterpene obtained from mint family plants
and is a popular ingredient in many foods and consumer
products (Bedoukian, 1983). Triterpenes such as squalene,
obtained from various plant sources and the livers of deep
sea sharks, have utility as a nutraceutical product, is used
extensively in many types of cosmetics, has special utility as
a lubricant for high performance machinery, and is a common adjuvant in many pharmaceutical formulations (Huang
et al., 2009; Reddy and Couvreur, 2009; Bhilwade et al.,
2010).
Terpenes are, however, generally made by plants and
microbes in small amounts and components of complex
mixtures that vary with growth and environmental conditions, making it difficult to reproducibly obtain large
amounts of any one terpene constituent (Wu et al., 2006).
Chemical synthesis ofterpenes is often costly and inefficient
(Nicolaou et al., 1994). Chemical synthesis also suffers from
generating enantiomeric mixtures, which adds other complications if one particular stereochemical form of a terpene
is desired. Given such difficulties, there are many on-going
efforts to create robust, reliable and efficient biological
systems for the production of distinct classes of terpenes,
and more so for the generation of stereochemically pure
forms of terpenes (Martin et al., 2003; Wu et al., 2006;
Takahashi et al., 2007; Asadollahi et al., 2008; Kirby et al.,
2008; Seki et al., 2008; Keasling, 2009; Asadollahi et al.,
2010; Fischer et al., 2011).

cell lines. In one further specific form of the present method,
the ergosterol dependent growth yeast are subject to an erg9
knockout mutation by inserting a foreign gene sequence into
the ergosterol dependent growth yeast at a location of erg9
to effect gene replacement, thereby generating the erg9
knockout mutation. In an alternative further method, the
foreign gene sequence can confer chemical resistance to the
ergosterol dependent growth/erg9 knockout mutation yeast
cell line.
The present invention, in another form thereof, relates to
a non naturally occurring yeast which has ergosterol dependent growth and is erg9-.
The present invention, in yet another form thereof relates
to ergosterol dependent growth/erg9 knockout mutation
yeast cell lines produced by the aforementioned method.
The present method and cell lines provide advantages
over wild type and other prior known modified yeast cell
lines. For example, the present method and resulting cell
lines are especially beneficial for use as terpene platforms
for further modification to specifically produce desired terpenes which include monodie and triterpenes.
The yeast lines generated in accordance with this disclosure have utility for the production of diverse classes of
terpenes including monoterpenes, sesquiterpenes, diterpenes
and triterpenes.
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SUMMARY OF THE INVENTION
The presently disclosed subject matter relates to methods
for producing modified yeast cell lines to produce "platforms" in yeast and the resulting modified yeast or platforms. The production platforms can be further modified to
produce specific terpenes such as monoterpenes, diterpenes
and/or triterpenes.
Referring generally to one specific technique for producing modified yeast cell lines in accordance with the present
disclosure, a series of steps are used to generate genetically
modified yeast. The steps include chemical mutagenesis
followed by growth on a semi-solid medium containing
nystatin, squalestatin and cholesterol. Individual yeast colonies growing on the semi-solid medium are screened for
ergosterol dependent growth and then subject to an erg9
(squalene synthase) knockout mutation. Yeast having the
erg9 knockout mutation are confirmed via having ergosterol
dependent growth. Accordingly, the present technique combines chemical mutagenesis to generate ergosterol dependent yeast lines followed by generating erg9- knockout
mutations in the ergosterol dependent yeast lines. One
unique aspect of this method includes the use of squalestatin
to screen chemically induced mutations in yeast which show
ergosterol dependent growth.
The present invention, or one form thereof relates to a
method for generating terpene producing cell lines. The
method includes combining yeast with a chemical mutagenesis agent to induce mutations in the yeast to generate
chemically mutated yeast. The chemically mutated yeast are
selected by growth in the presence of nystatin, squalestatin
and cholesterol, followed by selecting for ergosterol dependent growth. The ergosterol dependent growth yeast are
subjected to an erg9 knockout mutation to thereby produce
ergosterol dependent growth/erg9 knockout mutation yeast

35

40

45

50

55

60

65

FIG. 1 shows biosynthesis of terpenes from natural
sources, which often occurs as diverse mixtures with varying compositions in limited amounts due to environmental
influences, in which roduction of single specific terpenes in
genetically engineered yeast would alleviate such variability
and yield highly valued, single entity compounds.
FIG. 2 is schematic outline of two terpene biosynthetic
pathways that operate in plants (the MVA and MEP pathways), their intracellular locations, and examples of the
chemical compounds derived from each.
FIG. 3 illustrates mevalonate pathway for ergosterol biosynthesis in yeast (S. cerevisiae ).
FIG. 4 illustrates an alternative metabolic pathway for
HMG-CoA formation pathway through leucine catabolism
pathway.
FIG. 5 illustrates the metabolic pathway in modified yeast
strains in accordance with the present invention.
FIG. 6 is a flow diagram showing the biogenesis of
modified yeast in accordance with one aspect of the present
invention.
FIG. 7 is a graph showing metabolism of two strains
BY4741(A) and ZX178-08(B).
FIG. 8 illustrates how yeast strains produced in accordance with the present method can be used for producing
specific chemicals.
FIG. 9 shows how the yeast lines developed as outlined in
FIG. 8 in comparison to the starting yeast line 4741 were
chemically profiled for their terpene biosynthetic capacities.
FIG. 10 is a chart showing the production of various
compounds of different strains in accordance with the present invention.
FIG. 11 is a graph showing quantitation of FOH levels in
yeast lines having an exogenous stern! requirement growth.
FIG. 12 is a gel confirming erg9 knockout mutation in
accordance with the present invention.
FIG. 13 is a chart showing the quantitation ofFOH levels
in SUE, erg9 mutant lines of yeast demonstrated to have an
exogenous stern! requirement for growth and resistance to
hygromycin.
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FIG. 14 is a flow chart showing constructs used for
evaluate yeast sesquiterpene productions.
FIG. 15 is a flow diagram showing the steps in the
development of yeast.

line. In phase I, chemical mutagenesis is used to introduce
SUE mutations, which are identified by selecting for yeast
cells that do not have a functioning ergosterol biosynthetic
pathway and can only grow in the presence of exogenous
cholesterol. The SUE mutation was created by subjecting
wild type yeast strain BY4741 to EMS mutagenesis (see
supplemental materials and methods information for specifics) to introduce random mutations in the whole genome,
followed by selection on plates containing three important
selection agents: nystatin; cholesterol; and squalestatin.
Nystatin binds to ergosterol in the cell membrane causing
non-selective membrane permeability and leads to cell death
(Silva et al., 2006). Nystatin thus selects against cells that
have ergosterol in their membranes. However, yeast have an
absolute requirement for sterols in order for their membranes to function properly. Hence, by having the mutagenized yeast plated in the presence of cholesterol, which
nystatin camiot bind to, only yeast that can take up the
exogenous cholesterol under aerobic conditions and properly incorporate the cholesterol into their membranes survive. Squalestatin is a potent inhibitor of squalene synthase
and eliminates the yeast's ability to synthesize ergosterol
(Bergstrom et al., 1995), thus assuring that the surviving
yeast have a dispensable mevalonate pathway.
In phase II, yeast lines demonstrating an absolute requirement for exogenous sterols for growth were chemical profiled by GC-MS (FIG. 11). Aliquots of those yeast lines
exhibiting normal growth characteristics, having growth
rates comparable to wild type yeast, were extracted and their
chemical constituents separated by gas chromatography and
identified by their mass fragmentation patterns. The parental
line BY4741 does not accumulate detectable amounts of
FOH under these conditions. Mutant lines accumulating 50
or more mg/ml ofFOH were selected for phase III knockout
mutagenesis of the squalene synthase gene, ERG9.
As shown in FIG. 11, quantitation ofFOH levels in yeast
lines having an exogenous sterol requirement for growth.
Yeast lines were grown as test tube shake cultures with 3 ml
of YPD media containing 40 µg/ml of ergosterol and 40
µg/ml of squalestatin for 6 days prior to sampling the
cultures. One ml aliquots of cultures were mixed vigorously
with 1 ml of acetone, then allowed to stand for 15 min. One
ml of hexane containing a cedrene external standard was
then added, vortexed, centrifuged in a clinical centrifuge for
5 min, and the upper hexane phase removed and concentrated to 100 plunder a nitrogen stream. One µl aliquots of
the hexane extracts were then subjected to GC-MS and FOH
levels quantified relative to the external standard.
The objective in phase III was to obtain a knockout
mutation of the ERG 9 (squalene synthase) gene, thus
assuring the dispensable nature of the endogenous
mevalonate pathway for ergosterol biosynthesis. Site specific recombination was afford by appending 5' and 3'
regions surrounding the native ERG9 gene onto a hygromycin selection marker gene (see supplementary materials
and methods information), then introducing this linear gene
construct into selected yeast lines from the phase II screening under conditions to promote site-specific, double recombination with the native ERR9 gene. The knockout mutants
were then selected by plating the cells in the presence of
ergosterol and hygromycin. Recombination as depicted in
FIG. 6 should result in the coding region of the ERG9 gene
being displaced/substituted by the hygromycin resistance
marker gene. Confirmation of such a substitution event was
obtained by screening the genomic DNA of the selected
yeast colonies for the hygromycin marker gene in proximity
to genomic DNA sequences normally found 3' to the ERG9
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DETAILED DESCRIPTION
The present method and modified yeast will now be
described with reference to the figures and exemplary
experiments, examples and methods. The figures, experiments and examples are merely to provide a more thorough
understanding of the present method and modified yeast.
However, other methods and generated yeast can be envisioned consistent with the scope and spirit of the present
disclosure.
FIG. 5 illustrates one approach used to generate yeast cell
lines in accordance with the present disclosure. The
approach of FIG. 5 outlines a method for generating yeast
cell lines that provide for robust biosynthesis or precursors
that can be utilized in the production of many difference
classes of terpenes. The strategy takes advantage of the
native mevalonate (MVA) pathway that operates normally in
yeast for the biosynthesis of ergosterol, the dominant sterol
found in yeast. Ergosterol is the main product of the yeast
mevalonate pathway, is an important membrane component,
and is essential for yeast growth. If the ergosterol biosynthetic pathway is blocked or inhibited, yeast die. In fact, this
is the basis for many pharmacological drugs to control
fungal infections in man (Maertens, 2004) and agricultural
chemicals to control fungal infection in plants (Casida,
2009). To further complicate matters, wild type yeast can
take up exogenously supplied sterol from their environment
only under anaerobic conditions.
In order to be able to efficiently channel terpene biosynthetic intermediates from the ergosterol biosynthetic pathway, a SUE (sterol uptake enhancement) mutation supporting the aerobic uptake and utilization of exogenous sterol
was first created (Bourot and Karst, 1995; Shianna et al.,
2001 ). A SUE mutation is thus a yeast line that can meet all
its sterol needs by an exogenous source of sterol, and
therefore making the endogenous ergosterol biosynthetic
pathway dispensable. The SUE mutation was then complemented by the introduction of a knockout mutation in the
ERG9 gene (squalene synthase) (Zhang et al., 1993), resulting in a yeast line where the MVA pathway was still
operational up to the biosynthesis of FPP and hence, intermediates in the pathway (DMAPP, IPP and FPP) could be
diverted to the biosynthesis of other non-essential terpene
components. In order to follow and select for the desired
mutant lines, the yeast lines could be monitored for farnesol
(FOH) accumulation, the dephosphorylated form offarnesyl
diphosphate. If the MVA pathway in the yeast line continued
to operate as proposed, then one would expect carbon flux
to FPP to continue. But, because the downstream utilization
of FPP by squalene synthase was abolished, then the accumulating FPP would be subject to the endogenous phosphatase activity for its conversion to FOH, which could be
used as an initial screen for monitoring development of the
mutant yeast line. Further engineering of such a yeast line
could then take advantage of the FPP, DMAPP and IPPpools
for their diversion to the biosynthesis of monoterpenes (10
carbon compounds), sesquiterpenes ( 15 carbon compounds),
diterpenes (20 carbon compounds) and triterpenes (30 carbon compounds).
The following experiments were conducted to develop
yeast with a dispensible mevalonate pathway. FIG. 6 illustrates three (3) phases in the development of a desired yeast
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coding region. Using genomic DNA isolated from hygromycin resistant colonies as template with a hygromycin
specific primer (HphF) and a primer specific to a genomic
DNA sequence found 3' to the ERG9 gene (ERG9 450DwR),
a PCR amplification product of approximately 1,538 bp
would be expected and is evident in the colonies so tested in
FIG. 12.
In FIG. 12, PCR confirmation for the ERG9 knockout
mutation include DNA isolated from four independent colonies selected for substitution of the hygromycin resistance
gene for the ERG9 gene, used as PCR template with a
hygromycin specific primer and a specific primer for the
genomic DNA surrounding the ERG9 locust. If the HphF
gene did insert and replace the ERG9 gene, the expected
amplification product would be 1,538 bp. Independent colonies from each of the erg9 knockout lines were then reevaluated for their growth in liquid media and the dispensable nature of their mevalonate pathway checked by their
accumulation of FOH (FIG. 13).
As shown in FIG. 13, quantitation ofFOH levels in SUE,
erg9 mutant lines of yeast demonstrated to have an exogenous stern! requirement for growth and resistance to hygromycin. Cultures were grown in 3 ml test tube cultures of
SCE media supplemented with histidine, leucine, uracil,
tryptophan and methionine for 6 days before extracting and
quantifying their FOH levels by GC-MS as described in
FIG. 11.
Qualification of a New Mutant Yeast Strain for its Utility to
Produce a Desired Terpene Compound.
Nine of the yeast lines harboring a SUE mutation and
having the native ERG9 gene deleted were evaluated indirectly for the available of terpene biosynthetic intermediates,
and specifically FPP, to support sesquiterpene biosynthesis
in comparison to the parental strain BY4741 (FIG. 7).
Hyoscyamus prenmaspirodiene synthase (HPS), a catalytically active sesquiterpene synthase first isolated from
Hyoscyamus muticus, was chosen for this evaluation
because HPS has been characterized for its expression in
bacteria (Mathis et al., 1997) and in yeast (Takahashi et al.,
2007). An appropriate HPS gene expression vector was
engineered into the indicated yeast lines and the subsequent
transformants screened for premnaspirodiene accumulation
when the yeast were grown as 30 ml shake flask cultures
with SCE media containing leucine, tryptophan, uracil, and
methionine for 12 days at 23° C. Yeast line ZXl 78-08
accumulated the highest level of premnaspirodiene, up to
114±26 mg/L, with FOH levels of 23.6±14.5 mg/L. In
comparison, the parental line BY47 41 accumulated 10 times
less prenmaspirodiene, 10.94±3.12 mg/L, with no famesol
accumulation detected.
FIG. 9 shows a comparison of terpene accumulation
levels in yeast lines (ZX series) developed as terpene
production platforms. Each of the ZX cell lines as well as the
wild type parental line (BY4741) were independently transformed with an expression vector harboring the Hyoscyamus
prenmaspirodiene synthase gene. The yeast lines were then
grown for 12 days prior to chemically profiling them for
their cell constituents by GC-MS and quantifying the levels
of premnaspirodiene and famesol found in each.
The following experiments methods and procedures provide additional background with regard to the method for
producing terpene platforms in yeast and the resulting yeast
produced.
Chemical and Media Preparations
All chemical reagents were obtained from Sigma-Aldrich
(St. Louis, Mo.), BD Bioscience (Franklin Lakes, N.J.), or
Fisher Scientific (Chicago, Ill.), while reagents for molecu-

lar manipulations were from Stratagene (San Diego, Calif.),
Takara (Shiga, Japan), Invitrogen (San Diego, Calif.), and
New England Biolab (Ipswich, Mass.).
Bacteria and yeast were grown using standard culture
practices. YPD media for growing yeast without selection
consisted of 1% Bactoyeast extract, 2% Bacto-peptone, and
2% glucose (or 0.5% glucose for select experiments). YPDE
media was YPD media supplemented with ergosterol (40
mg/L) for ergosterol dependent lines. YPDNCS media for
the SUE mutation screening was YPD media supplement
with 40 mg/L Nystatin, 40 mg/L cholesterol and 40 mg/L
squalestatin. YPDSE media was YPD media supplement
with 40 mg/L squalestatin and 40 mg/L ergosterol. Minimal
media, SCE (pH 5.3), contained 0.67% Bacto-yeast nitrogen
base (without amino acids), 2% dextrose, 0.6% succinic
acid, 0.14% Sigma yeast dropout solution (-his,-leu,-ura,trp ), uracil (300 mg/L), L-tryptophan (150 mg/L), L-histidine (250 mg/L), L-methionine (200 mg/L), L-leucine (1
g/L) and 40 mg/L ergosterol. Cholesterol and ergostrol
stocks were 10 mg/mL in 50% Triton X-100, 50% ethanol
and kept at -20° C. Selection media was prepared similarly
except without supplementing the media with the indicated
reagent based on the yeast auxotrophic makers. All solid
media plates were prepared with 2% Bacto-Agar.
Ethyl Methane-Sulfonate (EMS) Mutagenesis
Strain BY47 41 (MATa;his3Al ;leu2A0;metl 5A0;ura3A0)
(Janke et al., 2004) was used as the parental yeast line.
BY4741 cells were incubated overnight at 30° C. in 5 ml
YPD medium with shaking at 200 rpm, and used to establish
a 200 ml YPD shake flask culture. When the yeast culture
OD600 reached approximately 1.0, the cells were spun
down by centrifugation (10 min at 4,000xg), and washed
twice with 20 ml 0.lM sodium phosphate buffer, pH7.0.
Cells were concentrated by centrifugation again, re-suspended in 1 ml 0. lM sodium phosphate buffer, transferred to
a 14 ml FALCON culture tubes, treated with 300 pi EMS
(1.2 g/ml, Sigma), followed by incubation at 30° C. for 1
hour with shaking. To stop the mutagenesis, 8 ml of sterile
5% sodium thiosulfate (Fisher) were added to yeast cells by
inactive EMS. Cells were pelleted, washed with 8 ml sterile
water, concentrated by centrifugation, re-suspended in 1 ml
sterile water and 100 pl aliquots plated onto YPD-NCS agar
plate (YPD plus 50 mg/L cholesterol, 50 mg/L nystatin, 50
mg/L squalesatin, 2% Bacto-agar). In some experiments, the
washed cells were resuspend in 1 ml YPDE liquid media for
recovery overnight before plating on YPD-NCS agar
medium. The cultures were incubated for up to 2 weeks at
30° C. until distinct colonies became visible.
Yeast Transformation and Culture Performance
Yeast strains were transformed with the respective vector
constructs using the FROZEN-EZ Yeast Transformation II
Kit (Zymo Research, Orange, Calif.) according to the manufacturer's recommendations. About 1 pg of plasmid or about
5 pg of linearized DNA was used per transformation and
followed by selection on agar plates of SCE medium lacking
specified amino acids for the auxotrophic markers or YPDE
containing 300 mg/L hygromycin B for screening for erg9
knockout at 30° C. Variable numbers of independent colonies were subsequently picked and used to start 3 ml cultures
in minimal media to characterize their terpene production
capacities. Aliquots of these cultures were analyzed for
terpene production after 6 days of incubation at 30° C. with
shaking by GC-MS. Cultures exhibiting the highest terpene
production levels were chosen for further studies and
archived as glycerol stocks at -80° C. Selected lines were
characterized for cell growth and terpene production using
30 mL shake flask cultures. Starter cultures grown to satu-
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ration in minimal media were inoculated into 30 ml SCE
media and 1 mL aliquots withdrawn at every other day
intervals for 10-15 days. Cell growth was monitored as the
change in optical density at 600 nm every two days, using
appropriate dilutions for cultures at later stages of growth.
Terpene production was determined by GC-MS similar to
the initial screening method.
GC-MS Detection and Quantification of Terpenes
To determine terpene accumulation levels, aliquots of
cultures grown for 6 to 12 days were extracted with hexane
and aliquots evaluated by GC-MS. In general, to 1 volume
of culture, 1 volume of acetone was added and mixed
vigorously for 3 to 5 min to lyre the cells. The sample was
then allowed to incubate at room temperature for 10 min
before adding 1 volume of hexane containing a known
amount of cedrene external standard. The mixture was again
mixed vigorously, then centrifuged in a clinical centrifuge
for 5 min at maximum speed. The upper organic layer was
collected and when necessary, concentrated under a N2
stream to ½o the original volume. An aliquot of the organic
phase (1 µ!) was then analyzed by GC-MS with a Varian
CP-3800 GC coupled to a Varian Saturn 2200 MS/MS
(Varian Medical Systems) using a Supelco SLB-5 ms fused
silica capillary column (30 mx0.25 mmx0.25 µm film thickness, Supelco). The initial oven temperature was set at 70°
C. for 1 min, ramped to 200° C. at 8° C./min, and then
ramped to 300° C. at 20° C./min and held for 5 min more.
Farnesol and prenmaspirodiene levels were calculated relative to the cedrene external standard.
Construction of the Squalene Synthase (ERG9) Knockout
Mutation
The primers ERG9PS1 and ERG-250downS2 were used
to amplify the hygromycin resistance gene, hphNTl, from
the PFA6-hph-NT1 vector (Janke et al., 2004), and at the
same time add DNA sequences homologous to regions
surrounding the ERG9 gene in the yeast genome. These
primers are flanked by 42 nucleotide sequences (underlined)
homologous to DNA sequences found 250 base pairs 5'
(upstream) and 3' (downstream), respectively, of the ERG9
gene found in the yeast genome. The purified PCR fragment
was transformed into various yeast lines identified for their
ability to accumulate farnesol (FIG. 11) and grown in 2 ml

ofYPDE media for an additional 6 hours before being plated
on YPDE hygromycin (300 mg/L) agar plates at 28° C.
Independent single colonies were picked for ergosterol
dependent test, PCR confirmation of recombination with
hphF and ERG9 450DWR primer, as well as farnesol
production analysis. The recombination sequence was further confirmed by DNA sequencing of a corresponding PCR
amplification product.
Expression of the HPS Gene in Yeast
The yeast GPD promoter (Pgpd) was amplified from the
PYM-N14 plasmid described by Janke et al. (2004) using
the primers GPD-BamHIF and GPD-NotIR primers and
inserted into the pESC-His vector digested with BamHl and
Not! to replace the original GALl/10 promoters. The resulting plasmid was named pESC-His-gpd. The HPS gene was
cloned into Not! and Spel sites of pESC-His-gpd to obtain
the yeast expression vector pESC-His-gpd-HPS as previously by Takahashi et al. (2007). Yeast lines transformed
with this construct were then evaluated for their production
of the sesquiterpene prenmaspirodiene as a measure of the
available of intermediates of the mevalonate biosynthetic
pathway for the biosynthesis of new terpenes.
Referring to FIG. 14, a yeast expression vector was
designed for a strong, consecutive expression of the sesquiterpene synthase HPS gene directed by the gpd promoter
(Pgpd) and termination provided by the ADH terminator
sequence (ADHterm).
In FIG. 15, steps are shown for the development of yeast
having a desirable mevalonate biosynthetic pathway and
number of colonies screened at each stage.
FIG. 8 shows FOH accumulation in a yeast line (178-08)
selected for a dispensable mevalonate biosynthetic pathway
in comparison to that accumulating in the parental line
(BY4741) used to generate the new mutant yeast lines.
GC-MS chromatograph of hexane extracts were prepared
from the wild type and engineered yeast lines. The top of
FIG. 8, for (A) BY4741, shows no farnesol accumulated in
parental yeast. In the bottom part of FIG. 8, (B) ZXl 78-08,
over 100 mg ofFOH/L accumulated in the newly developed
yeast line, as quantified on the basis of a cedrene external
standard.
The following table shows primers used in various
molecular manipulations described in the present disclosure.
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Primer Name

Primer sequence

ERG9p Sl

GTACATTTCATAGCCCATCTTCAACAACAATACCGACTTA
CCCGTACGCTGCAGGTCGAC

ERG9
250dw52

CAGATTGACGGAGAGAGGGCCACATTGTTTGTCGGCAA
TAAATCGATGAATTCGAGCTCG

Hph F

ATGGGTAAAAAGCCTGAACTCA

Hph R

TTATTCCTTTGCCCTCGGACGAG

ERG9
450cl Wr
ERG9p300upF

AGATGCTAGTCAATGGCAGAAG

ERG9 300R

CTCGTGGAAGTGACGCAAC

HPS Natl F

gggGCGGCCGCaAAAACA atggccccagctatagtgatgag

HPS SpeIR

gACTAGT tcaaatatcaatagaatccacc

pGPD-BamHIF

SegGGATCCagmatcattatcaatactcgcc

TGCTTACACAGAGTGAACCTGC

Sequence
Identifier
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NO: 3
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-continued
Primer Name

Primer sequence

pGPD-Not!R

gggGCGGCCGCgagctcagmatcattatc

It will be understood that various details of the presently
disclosed subject matter can be changed without departing
from the scope of the subject matter disclosed herein.
Furthermore, the foregoing description is for the purpose of
illustration only, and not for the purpose of limitation.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>
<220>
<223>

13

SEQ ID NO 1
LENGTH, 40
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, primer sequence

<400> SEQUENCE,

1

gtacatttca tagcccatct tcaacaacaa taccgactta

<210>
<211>
<212>
<213>
<220>
<223>

40

SEQ ID NO 2
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, primer sequence

<400> SEQUENCE, 2
cccgtacgct gcaggtcgac

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 3
LENGTH, 38
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, primer sequence

<400> SEQUENCE, 3
cagattgacg gagagagggc cacattgttt gtcggcaa

<210>
<211>
<212>
<213>
<220>
<223>

38

SEQ ID NO 4
LENGTH, 22
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, primer sequence

<400> SEQUENCE, 4
taaatcgatg aattcgagct cg

<210>
<211>
<212>
<213>
<220>
<223>

22

SEQ ID NO 5
LENGTH, 22
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, primer

<400> SEQUENCE, 5
atgggtaaaa agcctgaact ca

<210>
<211>
<212>
<213>
<220>
<223>

22

SEQ ID NO 6
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, primer

<400> SEQUENCE, 6
ttattccttt gccctcggac gag

<210>
<211>
<212>
<213>

SEQ ID NO 7
LENGTH, 22
TYPE, DNA
ORGANISM, Artificial Sequence

23
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-continued

<220> FEATURE,
<223> OTHER INFORMATION, primer
<400> SEQUENCE, 7
agatgctagt caatggcaga ag

<210>
<211>
<212>
<213>
<220>
<223>

22

SEQ ID NO 8
LENGTH, 22
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, primer

<400> SEQUENCE, 8
tgcttacaca gagtgaacct gc

<210>
<211>
<212>
<213>
<220>
<223>

22

SEQ ID NO 9
LENGTH, 19
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, primer

<400> SEQUENCE, 9
ctcgtggaag tgacgcaac

<210>
<211>
<212>
<213>
<220>
<223>

19

SEQ ID NO 10
LENGTH, 41
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, primer

<400> SEQUENCE, 10
ggggcggccg caaaaacaat ggccccagct atagtgatga g

<210>
<211>
<212>
<213>
<220>
<223>

41

SEQ ID NO 11
LENGTH, 29
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, primer

<400> SEQUENCE, 11
gactagttca aatatcaata gaatccacc

<210>
<211>
<212>
<213>
<220>
<223>

29

SEQ ID NO 12
LENGTH, 32
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, primer

<400> SEQUENCE, 12
cgggatccag tttatcatta tcaatactcg cc

<210>
<211>
<212>
<213>
<220>
<223>

32

SEQ ID NO 13
LENGTH, 31
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, primer

<400> SEQUENCE, 13
ggggcggccg cgagctcagt ttatcattat c

31
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The invention claimed is:
1. A non-naturally occurring yeast having:
(a) dispensable mevalonate and ergosterol biosynthetic
pathways, mutation(s) conferring the ability to use
exogenous stern! to meet its stern! requirements under
aerobic growth conditions in the presence of nystatin
and squalestatin but does not require exogenous stern!
in order to grow in the absence of nystatin and squalestatin;
(b) a wild type squalene synthase gene;
(c) harboring a mutation in one of the genes associated
with the enzymes comprising the mevalonate biosynthetic pathway or a mutation in a genetic locus effecting
production of farnesyl diphosphate or farnesol; and
(d) accumulating 50 mg/L or greater amounts of farnesol
when cultured in the presence of nystatin, squalestatin
and exogenous stern!,
said non-naturally occurring yeast produced by a method
comprising:
combining yeast with a chemical mutagenesis agent to
induce mutations in the yeast to generate chemically
mutated yeast;
culturing the chemically mutated yeast in the presence of
nystatin, squalestatin and cholesterol to produce yeast
which have (i) the dispensable stern! biosynthetic pathway, (ii) the ability to utilize exogenous sterols to meet
its aerobic growth needs in the presence of nystatin and
squalestatin but does not require exogenous stern! in
order to grow in the absence of nystatin and squalestatin, (iii) the dispensable mevalonate biosynthetic pathway due to one or more mutations introduced into loci
of an enzyme comprising the mevalonate biosynthetic
pathway other than the ERG9 gene locus or a mutation
in a genetic locus effecting production of farnesyl
diphosphate or farnesol, and (iv) a wild type squalene
synthase gene; and
selecting for yeast exhibiting stern! dependent growth and
farnesyl accumulation in an amount of 50 mg/L or
greater of farnesol when cultured in the presence of
nystatin and squalestatin to thereby produce the nonnaturally occurring yeast.
2. The non-naturally occurring yeast of claim 1, wherein
the yeast harbors a stern! uptake enhancement mutation
(SUE) or is phenotypically a SUE mutant.
3. The non-naturally occurring yeast of claim 1, wherein
the yeast is a mutant yeast selected from the group consisting
of Candida albicans and Saccharomyces cerevisiae.
4. A method for producing stern! dependent growth yeast
cell lines generating terpene, the method comprising:
combining yeast with a chemical mutagenesis agent to
induce mutations in the yeast to generate chemically
mutated yeast;
culturing the chemically mutated yeast in the presence of
nystatin, squalestatin and cholesterol to produce yeast
which have (i) a dispensable stern! biosynthetic pathway, (ii) an ability to utilize exogenous stern! to meet
its aerobic growth needs in the presence of nystatin and
squalestatin but does not require exogenous stern! in
order to grow in the absence of nystatin and squalestatin, (iii) a dispensable mevalonate biosynthetic pathway
due to one or more mutations introduced into loci of an
enzyme comprising the mevalonate biosynthetic pathway other than the ERG9 gene locus or a mutation in
a genetic locus effecting production of farnesyl diphosphate or farnesol, and (iv) a wild type squalene synthase gene; and

selecting for yeast exhibiting ergosterol dependent growth
and farnesyl accumulation in an amount of 50 mg/Lor
greater of farnesol when cultured in the presence of
nystatin and squalestatin.
5. The non-naturally occurring yeast of claim 1, in which
the yeast are from yeast line ZXl 78.
6. A stern! dependent growth/ERG9 gene knockout mutation (llerg9) yeast cell lines having:
(a) dispensable mevalonate and ergosterol biosynthetic
pathways, mutation(s) conferring the ability to use
exogenous stern! to meet its stern! requirements under
aerobic growth conditions in the presence of nystatin
and squalestatin but will require exogenous stern! in
order to grow in the absence of nystatin and squalestatin;
(b) the dispensable mevalonate and ergosterol biosynthetic pathway mutation(s) comprise replacement of
wild type ERG9 gene with a selectable marker gene;
(c) harboring a mutation in one of the genes associated
with the enzymes comprising the mevalonate biosynthetic pathway or a mutation in a genetic locus effecting
production of farnesol diphosphate or farnesol; and
(d) accumulating 60 mg/L or greater amounts of farnesol
when cultured in the presence of exogenous stern! but
not nystatin and squalestatin,
the stern! dependent growth/ERG9 gene knockout mutation (llerg9) yeast produced by a method comprising:
combining yeast with a chemical mutagenesis agent to
induce mutations in the yeast to generate chemically
mutated yeast;
culturing the chemically mutated yeast in the presence of
nystatin, squalestatin and cholesterol to produce the
yeast which have (i) the dispensable stern! biosynthetic
pathway, (ii) the ability to utilize exogenous sterols to
meet its aerobic growth needs in the presence of
nystatin and squalestatin but do not require exogenous
stern! in order to grow in the absence of nystatin and
squalestatin, (iii) the dispensable mevalonate biosynthetic pathway due to one or more mutations introduced
into loci of an enzyme comprising the mevalonate
biosynthetic pathway other than the ERG9 gene locus
or a mutation in a genetic locus effecting production of
farnesyl diphosphate or farnesol;
selecting for yeast with stern! dependent growth and
farnesol accumulation and for accumulating 50 mg/Lor
greater amounts of farnesol when cultured in the presence of nystatin, squalestatin and exogenous stern!; and
introducing the ERG9 gene mutation by gene replacement
of wild type ERG9 gene with an antimicrobial resistance gene to produce the yeast that (i) will require
exogenous stern! in order to grow when cultured in the
absence of nystatin and squalestatin, and (ii) have
farnesol accumulation in 60 mg/L or greater when
cultured in the presence of exogeneous stern!.
7. The non-naturally occurring yeast of claim 6, wherein
the yeast harbors a stern! uptake enhancement mutation
(SUE) or is phenotypically a SUE mutant.
8. A method for producing stern! dependent growth/ERG9
gene knockout mutation (llerg9) yeast cell lines, the method
comprising:
combining yeast with a chemical mutagenesis agent to
induce mutations in the yeast to generate chemically
mutated yeast;
culturing the chemically mutated yeast in the presence of
nystatin, squalestatin and cholesterol to produce yeast
which have (i) a dispensable stern! biosynthetic pathway, (ii) an ability to utilize exogenous sterols to meet

5

10

15

20

25

30

35

40

45

50

55

60

65

US 10,738,328 Bl

21
its aerobic growth needs in the presence of nystatin and
squalestatin but do not require exogenous sterol in
order to grow in the absence of nystatin and squalestatin, (iii) a dispensable mevalonate biosynthetic pathway
due to one or more mutations introduced into loci of an
enzyme comprising the mevalonate biosynthetic pathway other than the ERG9 gene locus or a mutation in
a genetic locus effecting production of famesyl diphosphate or farnesol;
selecting for yeast with sterol dependent growth and
famesol accumulation and for accumulating 50 mg/Lor
greater amounts of famesol when cultured in the presence of nystatin, squalestatin and exogenous sterol; and
introducing an ERG9 gene mutation by gene replacement
of wild type ERG9 gene with an antimicrobial resistance gene to produce yeast that (i) will require exogenous sterol in order to grow when cultured in the
absence of nystatin and squalestatin, and (ii) have
famesol accumulation in 60 mg/L or greater when
cultured in the presence of exogeneous sterol.

22
9. The yeast of claim 1, wherein the mutation is in one of

5

10

15

the genes encoding the enzymes of the mevalonate biosynthetic pathway.
10. The yeast of claim 6, wherein the mutation is in one
of the genes encoding the enzymes of the mevalonate
biosynthetic pathway.
11. The method of claim 8, further comprises introducing
an expression vector into the yeast cell line, which vector
expresses a gene for a terpene synthase.
12. The method of claim 11, wherein the terpene synthase
is for sesquiterpene synthase.
13. The sterol dependent growth yeast cell line of claim 6,
wherein the method producing the yeast cell line further
comprises introducing an expression vector into the yeast
cell line, which vector expresses a gene for terpene synthase.
14. The sterol dependent growth yeast cell line of claim
13, wherein the terpene synthase is for sesquiterpene.

* * * * *

